biotx.ai

🌟 Reflecting on 2023 🌟 As we approach the end of 2023, I find myself immensely proud to have engaged in profound discussions with over 250 biotech executives throughout the year. Amidst these conversations, a recurring challenge emerged—one that unites these innovative companies: the pressing issue of the reproducibility of academic results. Sadly, this isn't a new dilemma. A study by Prinz et al from Bayer in 2011 revealed that 65% of published data on drug targets lacks reproducibility: https://lnkd.in/ehnZQPRB This year, I witnessed firsthand the repercussions of this challenge, particularly for biotechs. Phase II studies faltered, and upon analysis, it became evident that foundational academic work was flawed. A biotech company facing a failed Phase II trial encounters the ultimate nightmare, often delivering a devastating blow that can lead to its demise. So, what's the solution? We need to #democratize the validation of academic results. It should be feasible to independently, swiftly, and cost-effectively validate academic results on a drug target. Excitingly, at biotx.ai, we're paving the way for just that. We will worker harder in 2024 to offer independent, fast, and cost-effective validation of any drug target using causal models based on large population biobank data. I'm thrilled to share that our collaboration with Simbec-Orion, a full-service CRO, is a significant stride towards early validation and improved study design. The synergy is promising, and I look forward to the impact we can collectively make. As the year draws to a close, I want to express my gratitude to our partners, customers, and the entire biotx.ai community. Here's to a Merry Christmas, a Happy New Year, and a future filled with impactful collaborations. Warm regards, Marco 🚀🎄✨